Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cadila Pharmaceuticals' (Cadila) plan to use virus-like particle (VLP) technology for the development of the H1N1 flu vaccines has been delayed, as the Drug Controller General of India (DCGI) has not cleared the initiation of clinical trials, reported DNA.
Subscribe to our email newsletter
Reportedly, the DCGI has asked the company to provide additional information about the technology to be used for the development of the vaccine.
Surinder Singh, chief drug controller general of India, said: “We have not given approval to Cadila as they are using a new technology called VLP and there is only vaccine that uses VLP technology right now. So the company needs to substantiate its credentials.
“We are still looking at the data they gave us and trials are also on in Mexico. It is being seen as new pathway for the vaccine, but on the other hand, we already have traditional vaccines so we need to be very cautious,” the website reported.
Cadila has singed a joint venture with Novavax for the development of VLP technology-based vaccines.